Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arcutis Biotherapeutics Inc shares valued at $168,799 were sold by Watanabe Todd on Sep 08 ’25. At $17.54 per share, Watanabe Todd sold 9,625 shares. The insider’s holdings dropped to 891,944 shares worth approximately $15.29 million following the completion of this transaction.
Also, Watanabe Todd sold 504 shares, netting a total of over 8,829 in proceeds. Following the sale of shares at $17.52 each, the insider now holds 891,440 shares.
Before that, Watanabe Todd had added 504 shares to its account. In a trade valued at $8,829, the Officer bought Arcutis Biotherapeutics Inc shares for $17.52 each.
As published in their initiating research note from Goldman on July 25, 2025, Arcutis Biotherapeutics Inc [ARQT] has been a Neutral and the price target has been revised to $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of August 28, 2024, Jefferies has initiated its “Buy” rating for ARQT. Earlier on January 03, 2024, Mizuho upgraded its rating. Their new recommendation was “a Buy” for ARQT stock which previously was a “a Neutral”.
Analyzing ARQT Stock Performance
On last trading session, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] rose 1.00% to $17.14. The stock’s lowest price that day was $17.05, but it reached a high of $17.8 in the same session. During the last five days, there has been a drop of approximately -2.45%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 60.79%.
Is Arcutis Biotherapeutics Inc subject to short interest?
Stocks of Arcutis Biotherapeutics Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.38 million shares to 17.02 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 16.64 million shares. A jump of 2.24% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.13 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.13.
Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?
In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, up nearly 11.96% from the previous closing price of $16.97. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 51 by 2025, with the lowest price target being 18. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 26, 2023, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
